Durham, North Carolina 27710


Purpose:

This is a parallel group, single institution, prospective clinical study. The purpose of this study is to assess whether the Jawbone Up 24, a consumer based accelerometer, can be a feasible tool to study physical activity in cancer patients and patients with Amyotrophic Lateral Sclerosis (ALS).


Criteria:

Inclusion Criteria: - Patients > = 18 years of age. - Patient must be able to ambulate and complete the 6 minute walk test without use of a walker, cane, or any assist devices. - Cancer patients or ALS patients who meet the following criteria: Prostate cancer: - Histologically confirmed prostate cancer. - Patients who are initiating any chemotherarpy (examples are docetaxel, cabazitaxel, etc.) and/or hormone directed treatment for prostate cancer. Examples of hormone directed therapy include GnRH agonist or antagonists (such as leuprolide, goserelin, triptorelin, histrelin and degarelix), androgen receptor blockers (such as bicalutamide or enzalutamide), or androgen biosynthesis inhibitors (such as abiraterone). Renal cancer: - Histologically confirmed renal cell carcinoma (RCC). - Metastatic disease, in the opinion of the treating provider. - Starting any systemic therapy for metastatic disease Brain cancer: - Histologically confirmed high grade glioma. - Status post concurrent radiation therapy and daily temozolomide. - Starting adjuvant temozolomide therapy. ALS patients who are: - Already on a stable dose of Riluzole for at least one month. - ALSFRS-R with <or equal to 2 point decline in last month. - Must have ALSFRS-R walking score of at least 3 or 4 and FVC at least 50% (to ensure patients are fit enough for ambulation and physical activity). - Technology requirement: - Patients will need to own a smart phone that can interface with the Jawbone Up 24. - Patients willing to provide their own internet access for this study. This will include either a data plan or Wi-Fi access on the patient's smart phone for use of the Jawbone App. They will also need internet access (through their smart phone or home computer) for setting up a SGHIx account. Patients are welcome to use the free guest Wi-Fi access within the Duke Outpatient clinic area for the purpose of this study. - Patients will need a home computer or adaptor with USB port to charge the Jawbone Up 24. Exclusion Criteria: - Non-English Speaking or inability to read and understand English - Presence of cardiovascular disease that would make physical activity risky at the discretion of the provider. - Any patient who is unable to comprehend and operate the activity tracker at the discretion of the enrolling provider.


NCT ID:

NCT02457715


Primary Contact:

Principal Investigator
Michael Harrison, MD
Duke University

Michael Harrison, MD
Email: michael.harrison@duke.edu


Backup Contact:

Email: julia.rasmussen@dm.duke.edu
Julia Rasmussen
Phone: 919-681-9822


Location Contact:

Durham, North Carolina 27710
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.